Catalogue Search | MBRL
Search Results Heading
Explore the vast range of titles available.
MBRLSearchResults
-
DisciplineDiscipline
-
Is Peer ReviewedIs Peer Reviewed
-
Series TitleSeries Title
-
Reading LevelReading Level
-
YearFrom:-To:
-
More FiltersMore FiltersContent TypeItem TypeIs Full-Text AvailableSubjectCountry Of PublicationPublisherSourceTarget AudienceDonorLanguagePlace of PublicationContributorsLocation
Done
Filters
Reset
2,192,305
result(s) for
"Martin, A."
Sort by:
Medical error—the third leading cause of death in the US
2016
Medical error is not included on death certificates or in rankings of cause of death. Martin Makary and Michael Daniel assess its contribution to mortality and call for better reporting
Journal Article
A single ectomycorrhizal fungal species can enable a Pinus invasion
by
Nuñez, Martin A.
,
Hayward, Jeremy
,
Horton, Thomas R.
in
Biological invasions
,
Chile
,
Coniferous forests
2015
Like all obligately ectomycorrhizal plants, pines require ectomycorrhizal fungal symbionts to complete their life cycle. Pines introduced into regions far from their native range are typically incompatible with local ectomycorrhizal fungi, and, when they invade, coinvade with fungi from their native range. While the identities and distributions of coinvasive fungal symbionts of pine invasions are poorly known, communities that have been studied are notably depauperate. However, it is not yet clear whether any number of fungal coinvaders is able to support a Pinaceae invasion, or whether very depauperate communities are unable to invade. Here, we ask whether there is evidence for a minimum species richness of fungal symbionts necessary to support a pine/ectomycorrhizal fungus coinvasion. We sampled a Pinus contorta invasion front near Coyhaique, Chile, using molecular barcoding to identify ectomycorrhizal fungi. We report that the site has a total richness of four species, and that many invasive trees appear to be supported by only a single ectomycorrhizal fungus, Suillus luteus. We conclude that a single ectomycorrhizal (ECM) fungus can suffice to enable a pine invasion.
Journal Article
Parton distributions from LHC, HERA, Tevatron and fixed target data: MSHT20 PDFs
2021
We present the new MSHT20 set of parton distribution functions (PDFs) of the proton, determined from global analyses of the available hard scattering data. The PDFs are made available at NNLO, NLO, and LO, and supersede the MMHT14 sets. They are obtained using the same basic framework, but the parameterisation is now adapted and extended, and there are 32 pairs of eigenvector PDFs. We also include a large number of new data sets: from the final HERA combined data on total and heavy flavour structure functions, to final Tevatron data, and in particular a significant number of new LHC 7 and 8 TeV data sets on vector boson production, inclusive jets and top quark distributions. We include up to NNLO QCD corrections for all data sets that play a major role in the fit, and NLO EW corrections where relevant. We find that these updates have an important impact on the PDFs, and for the first time the NNLO fit is strongly favoured over the NLO, reflecting the wider range and in particular increased precision of data included in the fit. There are some changes to central values and a significant reduction in the uncertainties of the PDFs in many, though not all, cases. Nonetheless, the PDFs and the resulting predictions are generally within one standard deviation of the MMHT14 results. The major changes are the u-d valence quark difference at small x, due to the improved parameterisation and new precise data, the d¯,u¯ difference at small x, due to a much improved parameterisation, and the strange quark PDF due to the effect of LHC W, Z data and inclusion of new NNLO corrections for dimuon production in neutrino DIS. We discuss the phenomenological impact of our results, and in general find reduced uncertainties in predictions for processes such as Higgs, top quark pair and W, Z production at post LHC Run-II energies.
Journal Article
Preaching on wax : the phonograph and the shaping of modern African American religion
\"From 1925 to 1941, approximately one hundred African American clergymen teamed up with leading record labels such as Columbia, Paramount, Victor-RCA to record and sell their sermons on wax. While white clerics of the era, such as Aimee Semple McPherson and Charles Fuller, became religious entrepreneurs and celebrities through their pioneering use of radio, black clergy were largely marginalized from radio. Instead, they relied on other means to get their message out, teaming up with corporate titans of the phonograph industry to package and distribute their old-time gospel messages across the country. Their nationally marketed folk sermons received an enthusiastic welcome by consumers, at times even outselling top billing jazz and blues artists such as Bessie Smith and Ma Rainey. These phonograph preachers significantly shaped the development of black religion during the interwar period, playing a crucial role in establishing the contemporary religious practices of commodification, broadcasting, and celebrity. Yet, the fame and reach of these nationwide media ministries came at a price, as phonograph preachers became subject to the principles of corporate America. In Preaching on Wax, Lerone A. Martin offers the first full-length account of the oft-overlooked religious history of the phonograph industry. He explains why a critical mass of African American ministers teamed up with the major phonograph labels of the day, how and why black consumers eagerly purchased their religious records, and how this phonograph religion significantly contributed to the shaping of modern African American Christianity\"-- Provided by publisher.
Energy conversion approaches and materials for high-efficiency photovoltaics
2017
This Review describes the sunlight conversion strategies — and their technological implementations — that are currently being investigated to realize solar cells with efficiencies beyond the Shockley–Queisser limit.
The past five years have seen significant cost reductions in photovoltaics and a correspondingly strong increase in uptake, with photovoltaics now positioned to provide one of the lowest-cost options for future electricity generation. What is becoming clear as the industry develops is that area-related costs, such as costs of encapsulation and field-installation, are increasingly important components of the total costs of photovoltaic electricity generation, with this trend expected to continue. Improved energy-conversion efficiency directly reduces such costs, with increased manufacturing volume likely to drive down the additional costs associated with implementing higher efficiencies. This suggests the industry will evolve beyond the standard single-junction solar cells that currently dominate commercial production, where energy-conversion efficiencies are fundamentally constrained by Shockley–Queisser limits to practical values below 30%. This Review assesses the overall prospects for a range of approaches that can potentially exceed these limits, based on ultimate efficiency prospects, material requirements and developmental outlook.
Journal Article
RNA interference in the era of nucleic acid therapeutics
by
Maier, Martin A.
,
Jadhav, Vasant
,
Vaishnaw, Akshay
in
631/337/505
,
631/61/2299
,
631/61/391/3932
2024
Two decades of research on RNA interference (RNAi) have transformed a breakthrough discovery in biology into a robust platform for a new class of medicines that modulate mRNA expression. Here we provide an overview of the trajectory of small-interfering RNA (siRNA) drug development, including the first approval in 2018 of a liver-targeted siRNA interference (RNAi) therapeutic in lipid nanoparticles and subsequent approvals of five more RNAi drugs, which used metabolically stable siRNAs combined with
N
-acetylgalactosamine ligands for conjugate-based liver delivery. We also consider the remaining challenges in the field, such as delivery to muscle, brain and other extrahepatic organs. Today’s RNAi therapeutics exhibit high specificity, potency and durability, and are transitioning from applications in rare diseases to widespread, chronic conditions.
With six approved drugs, siRNA is now an established therapeutic modality poised for expansion.
Journal Article